Anavex 2-73 Improves PD Symptoms, Study Says

Initially, biopharmaceutical company Anavex Life Sciences ("Anavex") developed Anavex 2-73 (blarcamesine) for patients with Alzheimer's disease. Now, the company has expanded its exploration of the therapy to determine its efficacy…

Continue Reading Anavex 2-73 Improves PD Symptoms, Study Says

Antipsychotic Use Falls in Patients with PD

In the past, antipsychotics were recommended as a potential treatment for patients with Parkinson's disease (PD). This is because, in later stages of PD, patients may experience Parkinson's psychosis, which…

Continue Reading Antipsychotic Use Falls in Patients with PD

tDCS Can Suppress Appetite in PWS

Hyperphagia, or an abnormally stronger hunger or desire to eat, is one of the characteristics of Prader-Willi syndrome (PWS), a rare genetic disorder. Because of this, patients with PWS often…

Continue Reading tDCS Can Suppress Appetite in PWS

IWMF Webinar Covers WM Peripheral Neuropathy

On May 4th The International Waldenstrom's Macroglobulinemia Foundation (IWMF) held another webinar in its 2021 IWMF Global Education series titled Peripheral Neuropathy: No Easy Feat. As the title implies, the…

Continue Reading IWMF Webinar Covers WM Peripheral Neuropathy

ION373 Clinical Trial Initiated for Alexander Disease

In a recent press release, RNA-targeted therapeutics company Ionis Pharmaceuticals, Inc. ("Ionis") shared the initiation of a Phase 2/3 clinical trial evaluating ION373 for patients with Alexander disease (AxD). Currently,…

Continue Reading ION373 Clinical Trial Initiated for Alexander Disease